sever
immunosuppress
drug
propos
secondlin
treatment
steroidrefractori
acut
graft
versu
host
diseas
agvhd
allogen
hematopoiet
stem
cell
transplant
howev
studi
drug
small
retrospect
uncontrol
use
differ
endpoint
therefor
remain
unknown
treatment
superior
retrospect
evalu
consecut
patient
treat
infliximab
agvhd
adher
recent
propos
guidelin
agvhd
trial
thu
evalu
respons
day
furthermor
assess
composit
endpoint
month
freedom
treatment
failur
major
patient
grade
iiiiv
agvhd
found
patient
respond
day
patient
day
twentyfour
patient
achiev
main
reason
failur
within
month
death
n
addit
immunosuppress
n
six
month
patient
aliv
respect
patient
respons
infliximab
day
significantli
higher
overal
surviv
os
probabl
nonrespond
show
respons
day
identifi
high
low
risk
group
patient
fail
respond
identifi
earli
offer
altern
therapi
electron
supplementari
materi
onlin
version
articl
http
contain
supplementari
materi
avail
author
user
acut
graft
versu
host
diseas
agvhd
common
sever
complic
hematopoiet
stem
cell
transplant
hsct
consensu
firstlin
treatment
mgkg
glucocorticoid
howev
steroidrefractori
patient
remain
unknown
treatment
option
superior
sever
secondlin
therapi
propos
add
immunosuppress
thu
increas
risk
infect
relaps
studi
show
effect
studi
secondlin
agent
prognosi
remain
poor
approxim
patient
surviv
month
comparison
studi
complic
small
number
studi
patient
lack
control
group
inconsist
treatment
schedul
differ
criteria
respons
assess
recent
guidelin
respons
assess
agvhd
studi
recommend
evalu
treatment
respons
fix
timepoint
furthermor
composit
endpoint
month
freedom
treatment
failur
increasingli
use
center
use
tumor
necrosi
factor
inhibitor
infliximab
secondor
furtherlin
treatment
agvhd
sinc
year
significantli
increas
patient
agvhd
inhibit
may
potenti
control
agvhd
inhibit
suggest
phase
agvhd
treatment
prevent
part
primari
agvhd
treatment
commonli
treatment
steroidrefractori
steroiddepend
agvhd
retrospect
evalu
adher
recent
propos
guidelin
respons
assess
intend
supplement
earlier
evid
effect
infliximab
secondlinetreat
valid
respons
day
secondorfurth
line
treatment
predict
surviv
propos
refer
guidelin
knowledg
largest
studi
patient
mainli
sever
steroidresist
agvhd
treat
infliximab
hope
elucid
role
infliximab
treatment
agvhd
singl
investig
mn
review
record
patient
treat
infliximab
patient
gave
inform
consent
use
data
studi
conduct
accord
direct
region
ethic
committe
myeloabl
condit
regimen
total
bodi
irradi
tbi
gy
cyclophosphamid
mgkg
etoposid
phosphat
mgm
busulphan
mgkg
plu
cyclophosphamid
mgkg
nonmyeloabl
regimen
tbi
cgi
case
cgi
combin
fludarabin
mgm
fludarabin
mg
without
tbi
graft
versu
host
diseas
prophylaxi
cyclosporin
csa
shortcours
methotrex
myeloabl
hsct
tacrolimu
tac
csa
mycophenol
mofetil
mmf
nonmyeloabl
hsct
donor
human
leucocyt
antigen
hla
ident
sibl
hlamatch
unrel
donor
except
two
singl
antigen
mismatch
classic
agvhd
occur
within
day
hsct
persist
lateonset
agvhd
includ
gastrointestin
gvhd
diagnos
histolog
examin
sigmoideum
biopsi
skin
gvhd
diagnos
presenc
typic
maculopapular
rash
liver
gvhd
diagnos
increas
serum
bilirubin
without
possibl
caus
grade
agvhd
assess
standard
criteria
insuffici
respons
standard
highdos
mgkg
glucocorticoid
treatment
defin
aggress
progress
de
novo
agvhd
grade
within
day
respons
week
therapi
inabl
taper
glucocorticoid
dose
initi
respons
glucocorticoid
taper
mgkg
reoccurr
agvhd
day
increas
glucocorticoid
dose
consid
start
current
agvhd
episod
baselin
agvhd
grade
score
day
infliximab
start
overal
respons
agvhd
assess
day
start
infliximab
treatment
complet
respons
cr
defin
resolut
indic
agvhd
good
partial
respons
vgpr
approxim
cr
describ
martin
et
al
partial
respons
pr
improv
one
grade
affect
organ
without
progress
de
novo
agvhd
organ
progress
note
organ
addit
treatment
administ
patient
classifi
progress
diseas
pd
chang
immunosuppress
due
side
effect
consid
pd
substitut
addit
immunosuppress
discret
treat
physician
stabl
diseas
sd
unalt
grade
affect
organ
day
respons
cr
vgpr
pr
consid
signific
treatment
effect
day
cr
vgpr
consid
signific
treatment
effect
also
evalu
failur
defin
death
relaps
malign
need
addit
system
immunosuppress
within
month
infliximab
use
label
steroidrefractori
steroiddepend
agvhd
allow
nation
health
author
patient
exclud
start
infliximab
treatment
due
poor
perform
statu
infect
financi
issu
standard
dosag
infliximab
mgkg
weekli
patient
pd
intensifi
schedul
two
dose
weekli
could
use
unless
sever
infect
pd
occur
infliximab
continu
patient
crvgpr
patient
receiv
posaconazol
liposom
amphotericin
b
acyclovir
valaciclovir
cotrimoxazol
dapson
neutrophil
count
l
ceftazidim
meropenem
administ
bodi
temperatur
exceed
blood
urin
sputum
cultur
taken
follow
preemptiv
antibiot
administr
quantit
pcr
analysi
cmv
blood
perform
weekli
posit
valganciclovir
ganciclovir
foscarnet
replac
acyclovirvalaciclovir
verifi
bacteri
fungal
viral
infect
record
month
start
infliximab
occurr
sever
life
threateningfat
infect
regist
accord
bmt
ctn
data
coordin
center
definit
infect
sever
http
definitiondefinitionsofinfseveritypdf
associ
baselin
variabl
day
respons
analyz
use
test
fisher
exact
test
categor
variabl
mannwhitney
test
continu
variabl
overal
surviv
os
probabl
estim
kaplanmei
method
comparison
done
log
rank
test
surviv
probabl
estim
start
infliximab
therapi
day
use
day
day
landmark
impact
surviv
patient
aliv
time
point
includ
analysi
statist
test
twotail
pvalu
consid
statist
signific
spss
softwar
version
use
statist
analysi
total
patient
receiv
allogen
hsct
center
develop
grade
iiiv
agvhd
sixtyeight
patient
receiv
infliximab
secondorfurtherlin
treatment
agvhd
patient
treatment
characterist
patient
shown
tabl
three
patient
develop
agvhd
donor
lymphocyt
infus
six
patient
second
transplant
initi
diagnosi
agvhd
patient
receiv
mgkg
methylprednisolon
mp
prednisolon
two
patient
start
lower
dose
increas
mgkg
due
progress
agvhd
infliximab
treatment
initi
nine
patient
receiv
less
mgkg
glucocorticoid
due
uncontrol
diabet
n
activ
cmv
infect
n
taper
prolong
steroid
treatment
n
taper
glucocorticoid
attempt
patient
agvhd
progress
necessit
increas
mgkg
thereaft
infliximab
start
infliximab
treatment
concomit
immunosuppress
medic
csa
n
tac
n
tac
mmf
n
csa
mmf
n
mmf
n
mmf
plu
sirolimu
n
four
patient
receiv
agvhd
therapi
prior
time
acut
lymphoid
leukemia
chronic
lymphocyt
leukemia
chronic
myeloid
leukemia
hodgkin
lymphoma
nonhodgkin
lymphoma
multipl
myeloma
sever
aplast
anemia
gastrointestin
liver
gastrointestin
skin
gastrointestin
liver
skin
start
infliximab
antithymocyt
globulin
atg
n
extracorpor
photopheresi
n
ultraviolet
phototherapi
n
median
three
infliximab
dose
rang
administ
within
day
schedul
administr
infliximab
standard
weekli
n
twice
weekli
n
twice
weekli
total
two
dose
n
one
dose
n
infliximab
stop
day
n
follow
reason
improv
agvhd
n
infect
n
progress
need
addit
treatment
n
death
n
addit
therapi
day
mmf
n
mmf
g
mp
n
daclizumab
atg
n
rituximab
n
sirolimu
n
addit
day
n
mmf
n
sirolimu
n
daclizumab
n
g
mp
sirolimu
n
eleven
patient
continu
infliximab
addit
therapi
wherea
infliximab
stop
prior
addit
five
patient
eight
patient
chang
immunosuppress
due
side
effect
usual
thrombot
microangiopathi
impair
kidney
function
glucocorticoid
dose
reduc
patient
median
week
rang
week
evalu
patient
receiv
glucocorticoid
n
mg
daili
n
mg
daili
n
overal
glucocorticoid
discontinu
patient
eventu
free
immunosuppress
medic
day
cr
vgpr
pr
obtain
patient
day
cr
vgpr
obtain
patient
includ
pr
day
respons
found
respons
rate
twentyfour
patient
achiev
major
crvgpr
day
n
reason
treatment
failur
within
month
death
n
addit
immunosuppress
n
see
flow
chart
fig
eight
patient
addit
treatment
day
one
cr
day
five
pd
two
die
variabl
significantli
predict
respons
day
day
grade
agvhd
start
infliximab
treatment
day
p
day
p
p
analysi
possibl
baselin
predictor
respons
shown
supplement
tabl
patient
gastrointestin
involv
significantli
posit
associ
crvgpr
day
p
endpoint
six
month
patient
aliv
respect
median
observ
time
month
rang
patient
respons
day
significantli
higher
os
probabl
nonrespond
os
rate
two
year
respect
overal
surviv
os
accord
infect
observ
patient
bacteri
infect
seen
viral
infect
fungal
infect
patient
microbiolog
agent
list
tabl
infecti
episod
classifi
sever
mean
studi
show
infliximab
effect
steroidrefractori
steroiddepend
agvhd
also
shown
previous
patriarca
et
al
report
patient
mainli
sever
agvhd
found
patient
cr
pr
day
couriel
et
al
evalu
patient
primarili
grade
ii
steroidrefractori
agvhd
found
respons
day
day
respons
compar
day
cr
vgprpr
rate
patient
mainli
sever
agvhd
pidala
et
al
report
patient
treat
infliximab
achiev
cr
median
day
rang
conclud
infliximab
may
limit
valu
grade
iiiiv
agvhd
contradict
find
major
patient
also
sever
agvhd
reason
poor
result
report
pidala
et
al
clear
may
due
less
intens
treatment
earli
respons
assess
pr
rate
state
studi
shown
martin
et
al
result
secondlin
treatment
variabl
agent
demonstr
activ
overal
crpr
rate
studi
interpret
caution
time
definit
respons
vari
furthermor
differ
patient
popul
includ
studi
five
report
respons
day
cr
proport
two
report
respons
day
crpr
proport
none
suggest
therapi
prove
superior
other
therefor
adher
recent
propos
guidelin
respons
assess
agvhd
facilit
comparison
within
studi
infliximab
also
therapeut
option
absenc
larg
random
control
studi
patient
treat
secondlin
therapi
agvhd
dismal
prognos
month
surviv
estim
confirm
find
high
earli
mortal
patient
aliv
month
respons
assess
day
primarili
test
firstlin
agvhd
treatment
especi
respons
day
shown
correl
strongli
longterm
endpoint
includ
surviv
secondlin
treatment
import
earli
predictor
treatment
success
respons
day
studi
valid
cr
vgpr
pr
day
either
cr
vgpr
day
predict
surviv
hypothes
pr
day
secondlin
therapi
indic
insuffici
treatment
effect
confirm
patient
pr
day
os
compar
patient
pd
day
earli
identif
patient
dismal
prognosi
import
agvhd
altern
therapi
initi
soon
possibl
found
low
incid
relaps
infect
substanti
problem
patient
sever
fatal
infect
despit
prophylact
antimicrobi
medic
marti
et
al
previous
report
increas
incid
noncandida
invas
fungal
infect
patient
treat
infliximab
agvhd
line
observ
invas
aspergillu
infect
et
al
found
incid
bacteri
viral
fungal
infect
respect
secondlin
treatment
agvhd
anticytokin
therapi
whether
patient
treat
infliximab
addit
differ
sever
infect
compar
treatment
conclud
data
care
monitor
patient
includ
relev
sampl
clinic
microbiolog
diagnosi
well
earli
aggress
antibiot
treatment
pivot
result
present
studi
limit
retrospect
natur
heterogen
patient
agvhdtreat
infliximab
initi
patient
affect
agvhd
variabl
period
time
variabl
system
immunosuppress
steroidrefractori
steroiddepend
patient
treat
infliximab
possibl
treatment
schedul
andor
durat
differ
differ
group
optim
treatment
schedul
infliximab
remain
unknown
addit
immunosuppress
administ
one
fourth
patient
could
potenti
account
respons
influenc
surviv
howev
sever
affect
patient
receiv
addit
therapi
found
addit
therapi
associ
wors
respons
day
seven
eight
pd
die
valid
present
largest
studi
infliximab
respons
day
abl
identifi
high
low
risk
group
secondorfurtherlin
treatment
patient
cr
vgpr
day
aliv
two
year
encourag
consid
major
patient
grade
iiiiv
agvhd
result
line
previous
publish
report
infliximab
secondlin
therapi
research
prefer
prospect
control
compar
endpoint
warrant
patient
fail
respond
identifi
earli
offer
altern
therapi
